Editorial: Advancement of RWD/RWE utilization for enhancing drug development and benefit/risk assessment
Authors:
Open Access
- 28 January 2026
- journal article
- editorial
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1787363
Abstract
Real-world data (RWD) and real-world evidence (RWE) have been utilized not only for drug safety assessment but also for effectiveness evaluation for drug approval on a global basis and many cases of RWD/RWE utilization for regulatory purposes have been accumulated with more diversifications in terms of data sources, methodology and study region (Kajiyama et al., 2024;Asano et al., 2025;Bachinger et al., 2025;Innes et al., 2025). Scientific discussions toward international harmonization related to RWD/RWE In conclusion, this research topic reflects a field of RWD/RWE utilization in transition from merely using RWD to actively strengthening RWE for decision-making use. The five studies provide a multifaceted view of the current state and emergingKeywords
This publication has 4 references indexed in Scilit:
- Real-World Evidence in Drug Approvals at the European Medicines AgencyJAMA Network Open, 2025
- Real‐World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020–2022Clinical Pharmacology & Therapeutics, 2025
- PMDA Perspective on Use of Real‐World Data and Real‐World Evidence as an External Control: Recent Examples and ConsiderationsClinical Pharmacology & Therapeutics, 2025
- PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing StagePharmacoepidemiology and Drug Safety, 2024